COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEY için istatistikler
Toplam ziyaret
| views | |
|---|---|
| COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEY | 0 |
Aylık toplam ziyaret
| views | |
|---|---|
| Mayıs 2024 | 0 |
| Haziran 2024 | 0 |
| Temmuz 2024 | 0 |
| Ağustos 2024 | 0 |
| Eylül 2024 | 0 |
| Ekim 2024 | 0 |
| Kasım 2024 | 0 |
